Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets
Significant growth round for Dxcover’s early stage cancer test
February 1, 2023
Read more
Delighted to welcome Waire Health Ltd to the Eos portfolio
January 24, 2023
Read more
Edinburgh’s Green Bioactives LTD Gains £2.6m Seed Funding
December 13, 2022
Read more
Bye bye microbead plastic pollution - the new website from Naturbeads - Eos is proud to be backing their growth
November 30, 2022
Read more
SEIS limit increased to £250k
October 3, 2022
Read more
Nodus Oncology launches, founded by Cumulus Oncology and in partnership with the Lead Discovery Center, to focus on developing first and best-in-class molecules inhibiting novel DNA damage response targets
September 6, 2022
Read more
Cleantech Startup Penrhos Bio Raises £1m with Support from Eos
September 5, 2022
Read more
Eos portfolio company, RAB-Microfluidics gets £2.2 million to scale-up oil analysis device
August 31, 2022
Read more
Eos portfolio company, Cumulus Oncology is the first oncology drug development accelerator in Europe.
August 23, 2022
Read more
Eos is supporting Ready Steady Grow! 2022
August 5, 2022
Read more
Spin-out company aiming to replace harmful plastic microbeads receives £1.3M investment
June 28, 2022
Read more
Andrew Durkie has joined Eos as a Partner alongside Andy Lothian and Sandy Kennedy as Growth Advisors as we work to support our portfolio of high impact companie
This website uses cookies to ensure you get the best experience on our website. By continuing to browse on this website, you accept the use of cookies for the above purposes.